🧾 Novartis India Ltd Q2 FY2025–26 Results: Steady Growth, Margin Pressure, and Management Outlook

🏢 Introduction

Novartis India Ltd, one of the country’s leading multinational pharmaceutical companies, announced its Q2 FY2025–26 financial results showcasing a stable performance in revenue and a year-on-year jump in net profit. The company has shown resilience in the face of pricing pressures, rising input costs, and a competitive pharma landscape.

In this detailed financial report, we analyze Novartis India’s Q2 FY2025–26 results, compare them with Q1 FY2025–26 and Q2 FY2024–25, and highlight management commentary and future guidance that investors should note.

📊 Novartis India Q2 FY2025–26 – Financial Performance Table

Source: Company filings & business media reports (Business Standard, MoneyControl, MarketsMojo)

💹 Revenue and Growth Analysis

Novartis India reported total revenue of ₹99.73 crore in Q2 FY2025–26, a 3.7% year-on-year growth compared to ₹97.42 crore in Q2 FY2024–25.

Sequentially, the company’s revenue rose by 1.6% compared to Q1 FY2025–26, showing steady top-line momentum despite a subdued pharma demand environment in India.

This performance was driven by:

• Strong demand for chronic therapies such as cardiovascular and immunology drugs.

• Stable portfolio of branded medicines, which continues to contribute the majority of domestic sales.

• Operational efficiency, especially in distribution and inventory management.

However, management also acknowledged pricing pressure in select generic segments, which limited higher revenue growth.

💰 Profit and Margin Performance

The company’s net profit increased to ₹24.22 crore in Q2 FY2025–26 from ₹20.41 crore in Q2 FY2024–25 — a growth of 18.7% year-on-year.

Yet, when compared to Q1 FY2025–26’s ₹27.62 crore, the net profit showed a decline of 12.3%, primarily due to:

• Rising input and distribution costs,

• Lower export realization, and

• Increased marketing expenditure to support product launches.

Despite the sequential dip, Novartis India maintained strong double-digit profitability with a net profit margin of 24.3%, reflecting effective cost management and premium product mix.

⚙️ Expense and Cost Management

Novartis India successfully reduced its total expenses to ₹67.08 crore in Q2 FY2025–26 from ₹69.86 crore in Q2 FY2024–25, showing improved efficiency.

Cost optimization initiatives included:

• Digital transformation in sales operations and distribution.

• Leaner logistics network reducing delivery costs.

• Strategic sourcing of raw materials from cost-efficient suppliers.

While expenses declined year-on-year, sequential cost pressures impacted operating margins slightly.

🧠 Operational Highlights

1. Portfolio Strength and Brand Focus

Novartis India continues to focus on core therapeutic segments — cardio, oncology, immunology, and neuroscience. The company’s strategy of strengthening high-value branded products has been central to its profitability.

2. Digital Transformation

In Q2 FY2025–26, Novartis further expanded its AI-driven analytics for sales forecasting and supply chain optimization. This digital push is helping improve sales productivity and reduce wastage in logistics.

3. R&D and Product Development

While the Indian arm focuses mainly on marketing and distribution, Novartis globally has invested in innovation pipelines. This allows Novartis India access to a steady flow of new launches aligned with global therapeutic advancements.

4. Sustainability Commitment

The company reaffirmed its environmental, social, and governance (ESG) goals, particularly in reducing carbon footprint and improving energy efficiency across its manufacturing and distribution chain.

🔍 Comparative Analysis

Interpretation:

• The company’s year-on-year performance is healthy and indicates resilience.

• The sequential fall in profit highlights temporary margin compression due to higher expenses.

• Cost efficiency programs are yielding results, as seen in the reduction of expenses YoY.

🗣️ Management Commentary and Guidance

During the Q2 results briefing, Novartis India’s management emphasized its commitment to sustainable growth and portfolio innovation.

Key Points from Management:

• The company expects mid-single-digit revenue growth for the full fiscal year FY2025–26.

• Focus remains on improving operating leverage through digital transformation and cost rationalization.

• Plans to launch new global molecules in India in FY2026 to strengthen the specialty medicine portfolio.

• Long-term outlook remains positive, driven by healthcare modernization and rising demand for chronic therapy drugs in India.

Quote from Management:

“Our strategy to strengthen core therapeutic areas and optimize cost structures continues to drive profitability despite near-term margin pressure. We remain committed to delivering long-term value for patients and shareholders.”

📈 Market Reaction and Analyst View

Following the announcement, Novartis India shares witnessed modest movement on the NSE, trading around ₹960–970 range on October 29, 2025.

Brokerage analysts from ICICI Direct and HDFC Securities maintained a ‘Hold to Positive’ outlook, citing:

• Stable margins,

• Robust balance sheet, and

• Healthy dividend policy.

Market experts suggest that sustained profit growth and new product launches could trigger further upside in coming quarters.

🌟 Outlook for FY2025–26

With an improved product mix, strong cost controls, and expansion in specialty therapies, Novartis India Ltd remains well-positioned for moderate yet stable growth.

Key growth drivers for H2 FY2025–26 include:

• Upcoming festive and seasonal demand,

• Increasing adoption of chronic therapies,

• Potential pricing reforms favoring premium brands.

However, watch for challenges like generic price erosion and global supply chain fluctuations, which could affect margins.

🧾 Conclusion

Novartis India Ltd’s Q2 FY2025–26 performance highlights a company balancing between steady revenue growth and disciplined cost control.

While the top line remains modest, profitability and expense efficiency demonstrate the company’s operational strength. The management’s focus on innovation, digitalization, and high-value therapies is expected to sustain growth momentum in the coming quarters.

In short:
✅ Revenue steady
✅ Profit up YoY
⚠️ Margin pressure QoQ
💡 Positive long-term outlook